CRIR Members

Dr. Ruth Perets

Phone number of Dr. Ruth Perets04-7776202

Dr. Ruth Perets is a Medical Oncologist  and Researcher in Rambam's Division of Oncology. She directs the Phase 1 Clinical Trials in Oncology and is the Head of the Women's Cancers Research Lab at Rambam Health Care Campus.

Dr. Perets graduated from the Faculty of Medicine of the Hebrew University at Hadassah Hospital, Jerusalem, where she completed both her MD and PhD degrees. Her doctoral thesis focused on the molecular role of the androgen receptor in prostate cancer, under the supervision of Prof. Eli Pikarsky. She completed her medical oncology residency at Rambam in 2015. During her residency she performed a post-doctoral fellowship at the Dana-Farber Cancer Institute in Boston, MA, under the supervision of Prof. Ronny Drapkin. There her studies focused on testing the hypothesis that the most common subtype of ovarian cancer, high grade serous carcinoma, originates from the fallopian tube in women with BRCA1/2 mutations and in the general female population.

Currently Dr. Perets focuses her clinical work on gynecological malignancies (ovarian, cervical and endometrial cancers) and breast cancer. Dr. Perets is the principal investigator of all Phase 1 clinical trials in Rambam’s Oncology Division, and personally treats most Phase 1 patients while on study. Furthermore, Dr. Perets is in charge of medical education in the division of oncology and among other roles in charge of the oncology residency program at Rambam Health Care Campus.

Dr. Perets is a member of the Clinical Research Institute at Rambam. Her research group focuses on understanding the early pathogenesis of ovarian cancer and evaluating the implications of early pathogenesis on treatment and prevention of ovarian cancer. She is also interested in drug development – from bench to bedside. Dr. Perets is an Assistant Professor at the Technion – Israel Institute of Technology, and a member of the Clinical Research Institute at Rambam (CRIR) and the Rappaport Technion Integrated Cancer Center (RTICC).

She is the recipient of numerous grants to study ovarian cancer pathogenesis and drug development, including the Israel Science Foundation grant for physician researchers, Israel Cancer Association grant, The FP7-Marie Curie reintegration grant, the women’s health at Rambam grant and the ICRF grants. She is the author of several highly cited scientific publications in the field of ovarian cancer, and performs peer review for oncology and pathology journals.

  • Research area:Research Area Early drug development
  • Key Word:Immunotherapy, Ovarian cancer, Endometrial Cancer, Gynecology Oncology, Fallopian tube, Mouse models, Drug development, Phase 1 clinical trials, Early phase clinical trials, First in human, Antibody Drug Conjugates, T-cell engagers
  • Category:Clinical Research
List of publications
on PubMed